Skip to main content
George Chen, MD, Hematology, Houston, TX

GeorgeLiweiChenMD

Hematology Houston, TX

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Roswell Park Cancer Institute

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161
    Fax+1 713-745-1782

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
  • The University of Texas Health Science Center at San Antonio
    The University of Texas Health Science Center at San AntonioClass of 1998

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - Present
  • FL State Medical License
    FL State Medical License 2024 - Present
  • AZ State Medical License
    AZ State Medical License 2024 - 2027
  • TN State Medical License
    TN State Medical License 2024 - 2026
  • TX State Medical License
    TX State Medical License 2000 - 2026
  • GA State Medical License
    GA State Medical License 2024 - 2025
  • LA State Medical License
    LA State Medical License 2024 - 2025
  • American Board of Internal Medicine Hematology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • _2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect
    George L. Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
    George L. Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Phase III SIERRA Trial Finds Iomab-B Promising for Relapsed/Refractory AML
    Phase III SIERRA Trial Finds Iomab-B Promising for Relapsed/Refractory AMLApril 8th, 2019